Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Aethlon Medical (NASDAQ: AEMD) reported its financial results for the third quarter ending December 31, 2022. The company continues developing the Hemopurifier®, focusing on cancer and life-threatening infectious diseases. A significant update includes a new oncology study set to initiate in Australia and the U.S. The company's cash balance stands at approximately $17.5 million, while operating expenses rose by 12% to roughly $2.85 million. Aethlon experienced a net loss of approximately $2.85 million, up from $2.53 million during the same period in 2021. The company did not record government contract revenue this quarter, impacting its financial results.
Aethlon Medical, Inc. (NASDAQ: AEMD) announced it will release its financial results for Q3 ended December 31, 2022, on February 6, 2023, at 4:15 p.m. EST. Following the results, a conference call will take place at 4:30 p.m. EST for management to discuss financial outcomes and corporate developments. The company focuses on developing the Hemopurifier, a clinical-stage device aimed at treating cancer and life-threatening infectious diseases. The Hemopurifier has received FDA Breakthrough Device designation due to its potential to remove harmful viruses and exosomes from blood.
Summary not available.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced its virtual presentation scheduled for February 2nd, 2023, at 10:00 AM ET, during the Sequire Biotechnology Conference. Led by Steven LaRosa, M.D., the presentation will outline the company's innovative medical technology aimed at treating cancer and severe infectious diseases. The biotechnology industry is projected to reach $727 billion by 2025, featuring over 6,500 US companies. Aethlon's main technology, the Hemopurifier, has received FDA Breakthrough Device designation and targets advanced cancer and life-threatening viral infections.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced a strategic agreement with NAMSA, a leading MedTech Contract Research Organization, to oversee clinical trials for its Hemopurifier device targeting cancer treatments. The trials will begin in Australia and include patients with various cancer tumors. Aethlon aims to expedite the clinical development of the Hemopurifier, which has shown promise in removing harmful exosomes and viruses from blood. The device is designated by the FDA as a Breakthrough Device for advanced or metastatic cancer therapies. This partnership is expected to enhance the efficiency and effectiveness of Aethlon's clinical research efforts.
Aethlon Medical, Inc. (AEMD) reported financial results for Q2 2022, with a net loss of approximately $3.8 million, a significant increase from $2.0 million in Q2 2021. Operating expenses rose to $3.67 million, up 71% year-over-year. The company has terminated its U.S. COVID-19 trial and head and neck cancer safety trial due to low patient enrollment, reallocating funds to advance the Hemopurifier in oncology research. As of September 30, 2022, Aethlon had a cash balance of $19.6 million and plans to launch a new oncology trial while engaging a new CRO in the U.S. and Australia.
Aethlon Medical (Nasdaq: AEMD) will announce its second-quarter financial results for the period ending September 30, 2022, on November 14, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss the results and corporate developments. The Hemopurifier, a breakthrough device, is being evaluated for treating cancer and infectious diseases. Notably, it has shown potential in removing harmful exosomes related to cancer and treating COVID-19 patients, demonstrating effectiveness in binding and removing the SARS-CoV-2 virus.
Aethlon Medical (Nasdaq: AEMD) announced participation in two key investor conferences in September 2022. The first is the H.C. Wainwright 24th Annual Global Investment Conference from Sept. 12-14, where pre-recorded presentations will be available on-demand from Sept. 12, 7:00 a.m. EDT. The second is the Life Sciences Investor Forum on Sept. 15, featuring a live presentation at 2 p.m. EDT. The presentations will highlight Aethlon's innovative Hemopurifier for treating cancer and infectious diseases, designed to remove harmful components from the bloodstream.
Aethlon Medical (AEMD) reported its financial results for the first quarter ending June 30, 2022, highlighting a cash balance of approximately $14.9 million. The company experienced a 30% increase in operating expenses, totaling around $2.91 million, primarily due to higher general and administrative costs. Revenue dropped from $132,000 in Q1 2021 to zero in the same period of 2022, resulting in a net loss of approximately $2.9 million. Aethlon is advancing clinical trials for its Hemopurifier® device targeting COVID-19 and cancer, and plans to assess its effectiveness against the monkeypox virus.
Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for the first quarter ending June 30, 2022, on August 9, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss the results and recent corporate developments. Interested parties can register for the call or dial in. The Hemopurifier, Aethlon's main product, has FDA Breakthrough Device designation for treating cancer and infectious diseases, showing promise in reducing harmful exosomes and viruses from blood, including SARS-CoV-2.